Investor Events and Presentations | Takeda Pharmaceuticals
IR calendar
Company Events & Broker Conferences FY2022 (April 2022-March 2023)
TAK-279 (TYK2 inhibitor) Investor Call on Phase 2b Psoriasis Data
(March 18, 2023)
QDENGA Investor call
(March 15, 2023)
Cowen 43rd Health Care Conference
(March 6, 2023)
41st Annual J.P. Morgan Healthcare Conference
(January 9, 2023)
Conference call regarding acquisition of NDI-034858 From Nimbus Therapeutics
(December 13, 2022)
Jefferies London Healthcare Conference
(November 15, 2022)
- This event was closed.
Seminar: Investors and Analysts on Lysosomal Storage Diseases (LSD)
(October 4, 2022)
Morgan Stanley Healthcare Conference
(September 12, 2022)
Jefferies Healthcare Conference
(June 9, 2022)
- This event was closed.
Past events
Cowen 42nd Health Care Conference
(2:50pm – 3:20pm EST on March 8, 2022)
- This event was closed.
Seminar: Investors and Analysts on Short Bowel Syndrome (SBS) and Complex Crohn’s Perianal Fistulas (CPF)
(1:00pm JST on February 24, 2022)
40th Annual J.P. Morgan Healthcare Conference
(4:30pm – 5:10pm EST on January 10, 2022)
Takeda Management Call
(6:00pm – 7:00pm EST on January 10, 2022)
Plasma-Derived Therapies Investor Event
(5:30pm – 7:30pm EST on November 17, 2021)
Finance Investor Day
(7:00pm – 9:00pm EDT on July 12, 2021)
Oncology Strategic Update Call
(6:30pm – 7:45pm EDT on June 8, 2021)
2021 Biopharma CEO Investor Forum
(8:00am – 8:50am EDT on June 7, 2021)
Wave 1 Pipeline Market Opportunity Call Part 2
(8:00am – 10:30am EDT on April 6, 2021)
Follow up call with R&D team: 9:00am-11:00am JST on April 21st
Growth and Emerging Markets Strategic Update Call
(6:30am-8:15am EST on March 11, 2021)
Seminar: Investors and Analysts on Takeda’s Japan Oncology Business and its oncology products and disease in Japan
(1:00pm-2:45pm JST on February 25, 2021)
World Conference on Lung Cancer (WCLC) Investor Event
(5:00pm-6:00pm EST on January 29, 2021)
39th Annual J.P. Morgan Healthcare Conference
(5:20pm-6:00pm EST on January 11, 2021)
Wave 1 Pipeline Market Opportunity Call
(5:00pm-7:15pm EST on December 8, 2020)
Seminar: Investors and Analysts on Inflammatory Bowel Disease
(1:00pm JST on September 2, 2020)
Seminar: Investors and Analysts on Hereditary Angioedema (HAE)
(1:00pm JST on June 30, 2020)
Oncology Focused Investor Call
(8:00am EDT / 9:00pm JST on June 8, 2020 )
38th Annual J.P. Morgan Healthcare Conference
(4:00pm-4:55pm PST on January 14, 2020)
- Presentation: J.P. Morgan Healthcare Conference Click to download
R&D Day and Plasma-Derived Therapies Day in Tokyo
(11:00am-5:00pm JST on November 21, 2019)
Plasma-Derived Therapies
Plasma-Derived Therapies Overview: Julie Kim, President, Plasma-Derived Therapies Business Unit
Plasma-Derived Therapies R&D: Christopher Morabito, Head, R&D, Plasma-Derived Therapies
R&D Day
Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader: Christophe Weber, President & CEO
Translating Science into Highly Innovative, Life-changing Medicines: Andy Plump, President, R&D
Oncology and Cell Therapies with Spotlight on CAR-NK: Chris Arendt, Head, Oncology Drug Discovery Unit
Spotlight on Oncology Opportunities TAK-788: Rachael Brake, Global Program Leader, Oncology
Spotlight on Oncology Opportunities Pevonedistat: Phil Rowlands, Head, Oncology Therapeutic Area Unit
Rare Diseases & Gene Therapy: Dan Curran, Head, Rare Disease Therapeutic Area Unit
Spotlight on Orexin2R agonists: Deborah Hartman, Global Program Leader, Neuroscience
Therapeutic Area Focus in GI with Spotlight on Celiac Disease: Asit Parikh, Head, GI Therapeutic Area Unit
Plasma-Derived Therapies Day in Covington, Georgia
(11:15am-3:45pm EST on November 15, 2019)
Plasma-Derived Therapies Overview: Julie Kim, President, Plasma-Derived Therapies Business Unit
Plasma-Derived Therapies R&D: Christopher Morabito, Head, R&D, Plasma-Derived Therapies
Covington Site Introduction: Carlos Soto, Covington Site Head
R&D Day in New York (12:30pm-4:00pm EST on November 14, 2019)
Welcome and Opening Remarks: Sheelagh Cawley-Knopf, Head, R&D Global Portfolio Strategy
Takeda: A Global Values-Based, R&D-Driven Biopharmaceutical Leader: Christophe Weber, President & CEO
Translating Science into Highly Innovative, Life-changing Medicines: Andy Plump, President, R&D
Oncology and Cell Therapies with Spotlight on CAR-NK: Chris Arendt, Head, Oncology Drug Discovery Unit
Spotlight on Oncology Opportunities TAK-788: Rachael Brake, Global Program Leader, Oncology
Spotlight on Oncology Opportunities Pevonedistat: Phil Rowlands, Head, Oncology Therapeutic Area Unit
Rare Diseases & Gene Therapy: Dan Curran, Head, Rare Disease Therapeutic Area Unit
Spotlight on Orexin2R agonists: Deborah Hartman, Global Program Leader, Neuroscience
Therapeutic Area Focus in GI with Spotlight on Celiac Disease: Asit Parikh, Head, GI Therapeutic Area Unit
IR meeting with analysts and investors with Julie Kim, President of Takeda's Plasma-Derived Therapies Business Unit
(Held on October 10, 2019)
- This event was closed.
Morgan Stanley Healthcare Conference
(Held on September 10, 2019 ET)
- This event was closed.
IR Seminar “Plasma-Derived Therapies Business”
(Held on July 12, 2019)
37th Annual J.P. Morgan Healthcare Conference
(Held on January 8, 2019 PST)
Meeting regarding Acquisition of Shire plc by Takeda
(Held on January 7th , 2019)
Presentation: A Global, Values-based, R&D-driven Biopharmaceutical Leader
Takeda’s R&D Investor Day (Boston)
(October 11, 2018)
Presentation: DELIVERING ON OUR R&D VISION
Andy Plump, Chief Medical and Scientific Officer
Takeda’s R&D Investor Day (Tokyo)
(September 27, 2018)
Andy Plump, Chief Medical and Scientific Officer
Conference Call Regarding Proposed Acquisition of Shire plc by Takeda
(Held on May 8/9, 2018)
- Presentation: Takeda to Acquire Shire-Accelerating Takeda’s Transformation to Deliver More for Patients
36th Annual J.P. Morgan Healthcare Conference
(Held on January 8, 2018 PST)
- This event was closed.
Jefferies 2017 Global Healthcare Conference
(Presented November 16, 2017, 10:00 GMT)
- This event was closed.
UBS Global Healthcare Conference
(Released on May 23, 2017, 9:30 EDT)
Conference Call on the Acquisition of ARIAD Pharmaceuticals
(Released on January 10, 2017)
35thAnnual J.P. Morgan Healthcare Conference
(Held on January 9, 2017)
Takeda IR Day
(Held on June 9, 2016)
Takeda Oncology: Christophe Bianchi, President, Global Oncology Business Unit
Focused World Class R&D New approaches to innovation: Andrew Plump, Chief Medical & Scientific Officer
Takeda IR Event: A Global Leader in Gastroenterology
(Held on March 9, 2015)
33rd Annual J.P. Morgan Healthcare Conference
(Held on January 13, 2015)
31st Annual J.P. Morgan Healthcare Conference
(Held on January 8, 2013)
Emerging Markets Meeting
(Held on August 28,2012)
Annual Shareholder meetings
146th Ordinary General Meeting of Shareholders
(June 29, 2022)
Items disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders
Message from Christophe Weber, President & CEO
Past Shareholder events
Notice of Convocation: Download
Items Disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders: Download
Message from Christophe Weber, President & CEO: Download
Takeda’s executive compensation overview: Download
Partial Correction to the Notice of Convocation of the 145th Ordinary General Meeting of Shareholders: Download
Notice of Resolutions: Download
Results of the Exercise of Voting Rights: Download
Notice of Convocation: Download
Items Disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders: Download
Message from Christophe Weber, President & CEO: Download
Takeda's executive compensation overview: Download
Partial Correction to the Items Disclosed via the Internet Concerning the Notice of Convocation of the 144th Ordinary General Meeting of Shareholders: Download
144th Ordinary General Meeting of Shareholders Christophe Weber: Download
Notice of Resolutions: Download
Results of the Exercise of Voting Rights: Download
Notice of Convocation: Download
Items Disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders: Download
Message from Christophe Weber, President & CEO: Download
Partial Correction to the Notice of Convocation of the 143rd Ordinary General Meeting of Shareholders: Download
Supplemental Material for the Proposals at the 143rd Ordinary General Meeting of Shareholders: Download
Summary of Takeda’s Modifications to the Executive Compensation Program and Future Considerations: Download
Takeda’s Recommendation to vote for Takeda’s Proposals at the 143rd Ordinary General Meeting of Shareholders: Download
A Statement of Confidence in the Leadership of Mr. Christophe Weber and Comments on the Proposals at the 143rd Ordinary General Meeting of Shareholders from Masahiro Sakane, the Chair of the Board of Directors Meeting of Takeda: Download
Consolidated Financial Results for FY2018 and Guidance for FY2019: Download
Notice of Resolutions: Download
Results of the Exercise of Voting Rights: Download
Notice of Convocation: Download
Message from Christophe Weber, President & CEO, regarding the acquisition of Shire plc: Download
Partial Correction to the Reference Document attached to the Notice of Convocation of the Extraordinary General Meeting of Shareholders: Download
Notice of Resolutions: Download
Results of the Exercise of voting Rights: Download
Notice of Convocation: Download
Items Disclosed via the Internet Concerning the Notice of Convocation of the Ordinary General Meeting of Shareholders: Download
Message from Christophe Weber, President & CEO, regarding recommended offer for Shire pic: Download
Consolidated Financial Results for FY2017 and Guidance for FY2018: Download
Notice of Resolutions: Download
Results of the Exercise of Voting Rights: Download
Retail Investor Event
February 22, 2023
Sign up for our investors newsletter
Stay up to date on financial results, corporate milestones and learn how we're delivering on our commitment to patients, our people and the planet
Sign up